Iron-induced platelet aggregation measurement: A novel method to measure platelet function in stenting for ST segment elevation myocardial infarction

European Journal of Clinical Investigation

Volumn 39, Issue 2, 2009, Pages 103-109

  Smit, J J J ^a,b   Van Oeveren, W ^b   Ottervanger, J P ^a,b   Slingerland, R J ^b,c   Remijn, J A ^b,c   Zijlstra, F ^d   Van T Hof, A W J ^a,b  

^a ISALA HOSPITAL   (Netherlands)

^b Gelre Ziekenhuizen ^*  (Netherlands)

^c GELRE HOSPITALS   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Iron induced platelet aggregation; Platelet function; Platelets; STEMI

Indexed keywords

ACETYLSALICYLIC ACID; APYRASE; CARBON; CLOPIDOGREL; HEPARIN; IRON; STEEL; TIROFIBAN;

ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY STENT; FEMALE; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

EID: 58649113434     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.02069.x     Document Type: Article

References (34)

1. Bertrand OF, Sipehia R, Mongrain R, Rodes J, Tardif JC, Bilodeau L et al. Biocompatibility aspects of new stent technology. J Am Coll Cardiol 1998 32 : 562 71.
2. Santin M, Mikhalovska L, Lloyd AW, Mikhalovsky S, Sigfrid L, Denyer SP et al. In vitro host response assessment of biomaterials for cardiovascular stent manufacture. J Mater Sci Mater Med 2004 15 : 473 7.
3. Rhodes NP, Shortland AP, Rattray A, Williams DF. Platelet reactions to modified surfaces under dynamic conditions. J Mater Sci Mater Med 1998 9 : 767 72.
4. Hietala EM, Maasilta P, Juuti H, Nuutinen JP, Harjula AL, Salminen US et al. Platelet deposition on stainless steel, spiral, and braided polylactide stents. A comparative study. Thromb Haemost 2004 92 : 1394 401.
5. Mrowietz C, Franke RP, Seyfert UT, Park JW, Jung F. Haemocompatibility of polymer-coated stainless steel stents as compared to uncoated stents. Clin Hemorheol Microcirc 2005 32 : 89 103.
6. Kolandaivelu K, Edelman ER. Environmental influences on endovascular stent platelet reactivity: an in vitro comparison of stainless steel and gold surfaces. J Biomed Mater Res A 2004 70 : 186 93.
7. Monnink SH, van Boven AJ, Peels HO, Tigchelaar I, de Kam PJ, Crijns HJ et al. Silicon-carbide coated coronary stents have low platelet and leukocyte adhesion during platelet activation. J Investig Med 1999 47 : 304 10.
8. Smit JJJ, van 't Hof AWJ, De Boer MJ, Hoorntje JCA, Dambrink JHE, Gosselink ATM et al. Incidence and predictors of subacute thrombosis in patients undergoing primary angioplasty for an acute myocardial infarction. Thromb Haemost 2006 96 : 190 5.
9. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007 28 : 1702 8.
10. van 't Hof AWJ, Hamm C, Rasoul S, Guptha S, Paolini J, ten Berg J. on behalf of the On-TIME 2 investigators. Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. Eurointerv 2007 3 : 371 80.
11. Ernst NMSKJ, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JCA et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST segment elevation myocardial infarction. J Am Coll Cardiol 2004 44 : 1187 93.
12. Carville DG, Schleckser PA, Guyker KE, Corsello M, Walsh MM. Whole blood platelet function assay on the ICHOR point-of-care haematology analyzer. J Extra Corpor Technol 1998 30 : 171 7.
13. Lakkis NM, George S, Thomas E, Ali M, Guyer K, Carville D. Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors. Catheter Cardiovasc Interv 2001 53 : 346 51.
14. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L et al. Profile and prevalence of Aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001 88 : 230 5.
15. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008 99 : 14 26.
16. Marshall PW, Williams AJ, Dixon RM, Growcott HW, Warburton S, Amstrong J et al. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 1997 44 : 151 5.
17. Smit JJJ, Hoorntje JCA, Miedema K, Van Oeveren W. Impaired platelet inhibitory effect of a single dose of acetylsalicylic acid in patients with unstable coronary artery syndrome in comparison with healthy volunteers. Neth Heart J 2004 12 : 265 70.
18. Van 't Hof AWJ, Ernst N, De Boer MJ, de Winter R, Boersma E, Bunt T et al. On-TIME study group. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004 25 : 837 46.
19. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB et al. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006 354 : 1464 76.
20. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004 109 : 3171 5.
21. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005 46 : 1827 32.
22. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004 110 : 1392 7.
23. Gibson CM, Jennings LK, Murphy SA, Lorenz DP, Giugliano RP, Harrington RA et al. INTEGRITI Study Group. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation 2004 110 : 679 84.
24. de Prado AP, Fernandez-Vazquez F, Cuellas JC, Alonso-Orcajo N, Carbonell R, Pascual C et al. Association between level of platelet inhibition after early use of abciximab and myocardial reperfusion in ST-elevation acute myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol 2006 97 : 798 803.
25. Smit JJJ, Ernst NM, Slingerland RJ, Kolkman JJ, Suryapranata H, Hoorntje JCA et al. on behalf of the On-TIME study group. Platelet microaggregation inhibition in patients with acute myocardial infarction pretreated with tirofiban and relationship with angiographic and clinical outcome. Am Heart J 2006 151 : 1102 7.
26. Welle A, Grunze M, Tur D. Plasma protein adsorption and platelet adhesion on poly[bis(trifluoroethoxy)phosphazene] and reference material surfaces. J Colloid Interface Sci 1998 197 : 263 74.
27. Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res 2006 118 : 487 93.
28. Jacopo G, Elisabetta V, Silverio S, Massimiliano M, Sergio B, Grazia AM et al. Identification of platelet hyper-reactivity measured with a portable device immediately after percutaneous coronary intervention predicts in stent thrombosis. Thromb Res 2007 121 : 407 12.
29. Chakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama MM, Hatmi M et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004 124 : 80 5.
30. Haubelt H, Anders C, Vogt A, Hoerdt P, Seyfert UT, Hellstern P. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals. Br J Haematol 2005 130 : 759 67.
31. Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H et al. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003 102 : 4594 9.
32. Golanski J, Pluta J, Baraniak J, Watala C. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists - in vitro experience. Clin Chem Lab Med 2004 42 : 25 9.
33. Hézard N, Metz D, Nazeyrollas P, Droulle C, Potron G, Nguyen P. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GpIIbIIIa blockers, in coronary angioplasty? Thromb Res 2002 108 : 43 7.
34. Sheth S, Litvack F, Dev V, Fishbein MC, Forrester JS, Eigler N. Subacute thrombosis and vascular injury resulting from slotted-tube nitinol and stainless steel stents in a rabbit carotid artery model. Circulation 1996 94 : 1733 40.